69 related articles for article (PubMed ID: 10515682)
1. The therapeutic potential of erythropoietin receptor transgenes.
Kirby SL
Cytokines Cell Mol Ther; 1999 Jun; 5(2):97-104. PubMed ID: 10515682
[TBL] [Abstract][Full Text] [Related]
2. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
3. In vivo expansion of gene-modified hematopoietic cells by a novel selective amplifier gene utilizing the erythropoietin receptor as a molecular switch.
Nagashima T; Ueda Y; Hanazono Y; Kume A; Shibata H; Ageyama N; Terao K; Ozawa K; Hasegawa M
J Gene Med; 2004 Jan; 6(1):22-31. PubMed ID: 14716674
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
7. Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.
Negre O; Fusil F; Henri A; Villette JM; Leboulch P; Beuzard Y; Payen E
Exp Hematol; 2008 Apr; 36(4):412-23. PubMed ID: 18295963
[TBL] [Abstract][Full Text] [Related]
8. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
9. Rapid immune reconstitution and dendritic cell engraftment post-bone marrow transplantation with heterogeneous progenitors and GM-CSF treatment.
Zhao P; Liu W; Cui Y
Exp Hematol; 2006 Jul; 34(7):951-64. PubMed ID: 16797423
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. In vivo selection using a cell-growth switch.
Jin L; Zeng H; Chien S; Otto KG; Richard RE; Emery DW; Blau CA
Nat Genet; 2000 Sep; 26(1):64-6. PubMed ID: 10973250
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation.
Kobayashi A; Hara H; Ohashi M; Nishimoto T; Yoshida K; Ohkohchi N; Yoshida T; Aoki K
Clin Cancer Res; 2007 Dec; 13(24):7469-79. PubMed ID: 18094431
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
Cui Y; Kelleher E; Straley E; Fuchs E; Gorski K; Levitsky H; Borrello I; Civin CI; Schoenberger SP; Cheng L; Pardoll DM; Whartenby KA
Nat Med; 2003 Jul; 9(7):952-8. PubMed ID: 12778137
[TBL] [Abstract][Full Text] [Related]
14. Graft facilitating cells are derived from hematopoietic stem cells and functionally require CD3, but are distinct from T lymphocytes.
Grimes HL; Schanie CL; Huang Y; Cramer D; Rezzoug F; Fugier-Vivier I; Ildstad ST
Exp Hematol; 2004 Oct; 32(10):946-54. PubMed ID: 15504550
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor.
Chen J; Jacobs-Helber SM; Barber DL; Sawyer ST
Exp Cell Res; 2004 Aug; 298(1):155-66. PubMed ID: 15242770
[TBL] [Abstract][Full Text] [Related]
16. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
[TBL] [Abstract][Full Text] [Related]
17. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice.
Kikuchi J; Mimuro J; Ogata K; Tabata T; Ueda Y; Ishiwata A; Kimura K; Takano K; Madoiwa S; Mizukami H; Hanazono Y; Kume A; Hasegawa M; Ozawa K; Sakata Y
J Gene Med; 2004 Oct; 6(10):1049-60. PubMed ID: 15386735
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for childhood immunological diseases.
Kohn DB
Bone Marrow Transplant; 2008 Jan; 41(2):199-205. PubMed ID: 17994122
[TBL] [Abstract][Full Text] [Related]
19. Myeloablation enhances engraftment of transduced murine hematopoietic cells, but does not influence long-term expression of the transgene.
Puig T; Kádár E; Limón A; Cancelas JA; Eixarch H; Luquín L; García M; Barquinero J
Gene Ther; 2002 Nov; 9(21):1472-9. PubMed ID: 12378410
[TBL] [Abstract][Full Text] [Related]
20. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
